442 related articles for article (PubMed ID: 17195452)
1. Possible applications of antibodies or their genes in cancer therapy.
Kuroki M; Huang J; Shibaguchi H; Tanaka T; Zhao J; Luo N; Hachimine K; Kinugasa T; Maekawa S; Enatsu S; Hamanaka W; Fukami T; Kuroki M
Anticancer Res; 2006; 26(6A):4019-25. PubMed ID: 17195452
[TBL] [Abstract][Full Text] [Related]
2. Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity.
Kuroki M; Hachimine K; Huang J; Shibaguchi H; Kinugasa T; Maekawa S; Kuroki M
Anticancer Res; 2005; 25(6A):3725-32. PubMed ID: 16302732
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy and gene therapy of cancer using antibodies or their genes against tumor-associated antigens.
Kuroki M; Shibaguchi H; Imakiire T; Uno K; Shirota K; Higuchi T; Shitama T; Yamada H; Hirose Y; Nagata A; Kuroki M
Anticancer Res; 2003; 23(6a):4377-81. PubMed ID: 14666724
[TBL] [Abstract][Full Text] [Related]
4. Novel treatment strategies for cancer and their tumor-targeting approaches using antibodies against tumor-associated antigens.
Kuroki M; Shirasu N
Anticancer Res; 2014 Aug; 34(8):4481-8. PubMed ID: 25075090
[TBL] [Abstract][Full Text] [Related]
5. T-cell receptor-like antibodies: novel reagents for clinical cancer immunology and immunotherapy.
Noy R; Eppel M; Haus-Cohen M; Klechevsky E; Mekler O; Michaeli Y; Denkberg G; Reiter Y
Expert Rev Anticancer Ther; 2005 Jun; 5(3):523-36. PubMed ID: 16250828
[TBL] [Abstract][Full Text] [Related]
6. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies.
Majidi J; Barar J; Baradaran B; Abdolalizadeh J; Omidi Y
Hum Antibodies; 2009; 18(3):81-100. PubMed ID: 19729803
[TBL] [Abstract][Full Text] [Related]
7. Possible targets on carcinoma for bMAb retargeting of lymphocyte or drug cytotoxicity.
Canevari S; Mezzanzanica D; Ménard S; Ferrini S; Moretta L; Colnaghi MI
Int J Cancer Suppl; 1992; 7():42-4. PubMed ID: 1428402
[TBL] [Abstract][Full Text] [Related]
8. Natural T cell immunity against cancer.
Nagorsen D; Scheibenbogen C; Marincola FM; Letsch A; Keilholz U
Clin Cancer Res; 2003 Oct; 9(12):4296-303. PubMed ID: 14555498
[TBL] [Abstract][Full Text] [Related]
9. Cancer immunotherapy.
Schuster M; Nechansky A; Kircheis R
Biotechnol J; 2006 Feb; 1(2):138-47. PubMed ID: 16892244
[TBL] [Abstract][Full Text] [Related]
10. Antibody-guided radiation therapy of cancer.
Koppe MJ; Postema EJ; Aarts F; Oyen WJ; Bleichrodt RP; Boerman OC
Cancer Metastasis Rev; 2005 Dec; 24(4):539-67. PubMed ID: 16408161
[TBL] [Abstract][Full Text] [Related]
11. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies.
Iannello A; Ahmad A
Cancer Metastasis Rev; 2005 Dec; 24(4):487-99. PubMed ID: 16408158
[TBL] [Abstract][Full Text] [Related]
12. New approaches to antibody therapy.
Weiner LM; Adams GP
Oncogene; 2000 Dec; 19(53):6144-51. PubMed ID: 11156528
[TBL] [Abstract][Full Text] [Related]
13. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.
Peggs KS; Quezada SA; Korman AJ; Allison JP
Curr Opin Immunol; 2006 Apr; 18(2):206-13. PubMed ID: 16464564
[TBL] [Abstract][Full Text] [Related]
14. Cancer immunotherapy of targeting angiogenesis.
Hou J; Tian L; Wei Y
Cell Mol Immunol; 2004 Jun; 1(3):161-6. PubMed ID: 16219162
[TBL] [Abstract][Full Text] [Related]
15. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal and bispecific antibodies as novel therapeutics.
Booy EP; Johar D; Maddika S; Pirzada H; Sahib MM; Gehrke I; Loewen S; Louis SF; Kadkhoda K; Mowat M; Los M
Arch Immunol Ther Exp (Warsz); 2006; 54(2):85-101. PubMed ID: 16648969
[TBL] [Abstract][Full Text] [Related]
17. Antibody-based therapeutics: focus on prostate cancer.
Ross JS; Gray KE; Webb IJ; Gray GS; Rolfe M; Schenkein DP; Nanus DM; Millowsky MI; Bander NH
Cancer Metastasis Rev; 2005 Dec; 24(4):521-37. PubMed ID: 16408160
[TBL] [Abstract][Full Text] [Related]
18. Targeting cancer stem cells with monoclonal antibodies: a new perspective in cancer therapy and diagnosis.
Okamoto OK; Perez JF
Expert Rev Mol Diagn; 2008 Jul; 8(4):387-93. PubMed ID: 18598221
[TBL] [Abstract][Full Text] [Related]
19. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
[TBL] [Abstract][Full Text] [Related]
20. Antibody engineering: facing new challenges in cancer therapy.
Sanz L; Cuesta AM; Compte M; Alvarez-Vallina L
Acta Pharmacol Sin; 2005 Jun; 26(6):641-8. PubMed ID: 15916728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
